835 related articles for article (PubMed ID: 21486625)
1. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation.
Cimsit B; Assis D; Caldwell C; Arvelakis A; Taddei T; Kulkarni S; Schilsky M; Emre S
Transplant Proc; 2011 Apr; 43(3):905-8. PubMed ID: 21486625
[TBL] [Abstract][Full Text] [Related]
2. Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection.
Delladetsima JK; Boletis JN; Makris F; Psichogiou M; Kostakis A; Hatzakis A
Liver Transpl Surg; 1999 Jul; 5(4):294-300. PubMed ID: 10388502
[TBL] [Abstract][Full Text] [Related]
3. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin.
Gopal DV; Rabkin JM; Berk BS; Corless CL; Chou S; Olyaei A; Orloff SL; Rosen HR
Liver Transpl; 2001 Mar; 7(3):181-90. PubMed ID: 11244158
[TBL] [Abstract][Full Text] [Related]
4. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C.
Ross AS; Bhan AK; Pascual M; Thiim M; Benedict Cosimi A; Chung RT
Clin Transplant; 2004 Apr; 18(2):166-73. PubMed ID: 15016131
[TBL] [Abstract][Full Text] [Related]
5. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series.
Rodriguez-Luna H; Khatib A; Sharma P; De Petris G; Williams JW; Ortiz J; Hansen K; Mulligan D; Moss A; Douglas DD; Balan V; Rakela J; Vargas HE
Transplantation; 2004 Jan; 77(2):190-4. PubMed ID: 14742979
[TBL] [Abstract][Full Text] [Related]
6. Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post-orthotopic liver transplant.
Kwo PY; Ghabril M; Lacerda MA; Joseph Tector A; Fridell JA; Vianna R
Clin Transplant; 2014 Jun; 28(6):722-7. PubMed ID: 24708229
[TBL] [Abstract][Full Text] [Related]
7. Incidence and severity of acute allograft rejection in liver transplant recipients treated with alfa interferon.
Jain A; Demetris AJ; Manez R; Tsamanadas AC; Van Thiel D; Rakela J; Starzl TE; Fung JJ
Liver Transpl Surg; 1998 May; 4(3):197-203. PubMed ID: 9563957
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with sustained virological response in liver transplant recipients with recurrent hepatitis C.
Pillai AA; Lee VS; Wang E; Rinella ME; Levitsky J
Transplant Proc; 2010 Nov; 42(9):3647-51. PubMed ID: 21094833
[TBL] [Abstract][Full Text] [Related]
9. First successful treatment of post-liver transplant hepatitis C fibrosing cholestatic hepatitis with boceprevir, peginterferon and ribavirin in a pre-transplant null responder.
Al Nahdi N; Ford JA; Greanya ED; Harrigan JA; Tse I; Steinbrecher UP; Erb SR; Yoshida EM
Ann Hepatol; 2013; 12(1):156-60. PubMed ID: 23293209
[TBL] [Abstract][Full Text] [Related]
10. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation.
Pungpapong S; Aqel BA; Koning L; Murphy JL; Henry TM; Ryland KL; Yataco ML; Satyanarayana R; Rosser BG; Vargas HE; Charlton MR; Keaveny AP
Liver Transpl; 2013 Jul; 19(7):690-700. PubMed ID: 23696372
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus viral kinetics during α-2a or α-2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immunosuppression regimes.
Berenguer M; Ortíz-Cantó C; Abellán JJ; Aguilera V; Rubín A; Prieto M; López-Labrador FX
J Clin Virol; 2012 Mar; 53(3):231-8. PubMed ID: 22222052
[TBL] [Abstract][Full Text] [Related]
12. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
Ramirez CB; Doria C; di Francesco F; Iaria M; Kang Y; Marino IR
J Surg Res; 2007 Apr; 138(2):198-204. PubMed ID: 17292404
[TBL] [Abstract][Full Text] [Related]
13. Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report.
Kawaoka T; Imamura M; Kan H; Fujino H; Fukuhara T; Kobayashi T; Honda Y; Naeshiro N; Hiramatsu A; Tsuge M; Hayes CN; Kawakami Y; Aikata H; Ochi H; Ishiyama K; Tashiro H; Ohdan H; Chayama K
Transplant Proc; 2015 Apr; 47(3):809-14. PubMed ID: 25891736
[TBL] [Abstract][Full Text] [Related]
14. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.
Stravitz RT; Shiffman ML; Sanyal AJ; Luketic VA; Sterling RK; Heuman DM; Ashworth A; Mills AS; Contos M; Cotterell AH; Maluf D; Posner MP; Fisher RA
Liver Transpl; 2004 Jul; 10(7):850-8. PubMed ID: 15237368
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of interferon in immunocompromised HCV patients after liver transplantation or with HIV co-infection.
Reiberger T; Rasoul-Rockenschaub S; Rieger A; Ferenci P; Gangl A; Peck-Radosavljevic M
Eur J Clin Invest; 2008 Jun; 38(6):421-9. PubMed ID: 18489402
[TBL] [Abstract][Full Text] [Related]
16. Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant.
Papadopoulos-Köhn A; Achterfeld A; Paul A; Canbay A; Timm J; Jochum C; Gerken G; Herzer K
Transplantation; 2015 Apr; 99(4):841-7. PubMed ID: 25208324
[TBL] [Abstract][Full Text] [Related]
17. Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient.
Montalbano M; Pasulo L; Sonzogni A; Remuzzi G; Colledan M; Strazzabosco M
J Clin Gastroenterol; 2007 Feb; 41(2):216-20. PubMed ID: 17245223
[TBL] [Abstract][Full Text] [Related]
18. Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis.
Saab S; Jimenez M; Bau S; Goo T; Zhao D; Durazo F; Han S; El Kabany M; Kaldas F; Tong MJ; Busuttil RW
Clin Transplant; 2015 Sep; 29(9):813-9. PubMed ID: 26147216
[TBL] [Abstract][Full Text] [Related]
19. Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study.
Tanaka T; Sugawara Y; Akamatsu N; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Kurosaki M; Izumi N; Kokudo N
J Hepatobiliary Pancreat Sci; 2015 Feb; 22(2):144-50. PubMed ID: 25338946
[TBL] [Abstract][Full Text] [Related]
20. Fibrosing cholestatic hepatitis after successful interferon and ribavirin therapy for recurrent hepatitis C post living related liver transplantation: a case report.
Yamamoto T; Tanaka S; Uenishi T; Kanazawa A; Kubo S; Hirohashi K
Osaka City Med J; 2014 Dec; 60(2):95-100. PubMed ID: 25803885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
